Healthcare shares split as clinical progress meets cash pressure
Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
- AdAlta and Skin Elements were the week’s weakest movers, each falling 33.33%.
- Mesoblast rose 27.32% after higher Ryoncil revenue and a possible FDA filing for a heart-failure treatment.
- Lumos fell 27.71% despite wider US use of FebriDx, as paediatric enrolment slowed and a Hologic timeline moved out.
- Cash remains a central issue, with AdAlta, Chimeric, Nexalis and Cann Group holding less than one quarter of reported funding.
- Several companies advanced towards major trials or regulatory decisions due in late 2026 or 2027.
Add us as a preferred source on Google
AdAlta Therapeutics (ASX:1AD) and Skin Elements (ASX:SKN) posted the largest falls, each down 33.33%. Mesoblast (ASX:MSB) was the strongest mover, rising 27.32%. Lumos Diagnostics (ASX:LDX) also fell heavily, down 27.71%.
Big moves, different reasons
AdAlta is preparing for a US FDA meeting on its EW-001 CAR-T treatment. It had only A$650,000 in cash at quarter end. That leaves little room for delays before expected tax incentive money arrives. Skin Elements secured A$700,000 for product sales and working capital, but the deal includes 318.2 million free options. Future share dilution may have worried investors.
Mesoblast offered a more supportive update. First-quarter Ryoncil revenue rose 44% to US$28 million, while operating cash use fell sharply. The FDA also confirmed that Mesoblast may file for approval of a treatment for life-threatening gastrointestinal bleeding in certain heart-failure patients. Investors now have a clearer set of commercial and regulatory events to watch.
Lumos expanded FebriDx to 265 US healthcare sites, but product revenue was still only US$564,000. The company used US$4.7 million in operations during the quarter. Slower enrolment in a children’s study and a Hologic development date moving to about June 2028 added uncertainty. The share fall shows that wider product use did not remove concerns about cash use and delays.
Trials move forward, but cash sets the pace
Clinical progress continued across the sector. Clarity Pharmaceuticals (ASX:CU6) completed recruitment of 383 people for its prostate cancer imaging trial. Top-line results are due in the first half of 2027. Arovella Therapeutics (ASX:ALA) dosed the first patient in its blood cancer trial, with early data expected in 2027. Neurotech International (ASX:NTI) also began its pivotal autism trial, but its A$5.2 million cash balance covered only 1.24 quarters of past spending.
Several companies face a nearer funding test. Chimeric Therapeutics (ASX:CHM) stopped its CAR-T trial after the highest dose caused serious safety problems. It had A$1.35 million in cash, equal to 0.80 quarters of reported funding. Nexalis Therapeutics (ASX:NX1) held $371,000 after its clinical programmes paused. Cann Group (ASX:CAN) grew quarterly revenue to $3.45 million, yet ended the period with only $49,000 in cash.
Commercial growth meets higher costs
Some established products are gaining customers, but sales do not always cover the cost of growth. Botanix Pharmaceuticals (ASX:BOT) shipped 35,130 Sofdra prescriptions, up 5.3%, while cash fell to $24.4 million. The company plans to cut operating costs by about half. Integral Diagnostics (ASX:IDX) expects 4% to 6% revenue growth, but staff shortages pushed labour costs higher and reduced its profit margin outlook.
There were stronger operating results elsewhere. Biome Australia (ASX:BIO) reported positive operating cash flow as pharmacy sales rose. Cyclopharm (ASX:CYC) lifted US Technegas revenue 124% and installed 84 revenue-generating systems. Third Age Health (ASX:TAH) increased first-half profit by 38.4%. These companies still need to turn customer growth into reliable profits and cash over time.
Capital raising remains part of the plan
Invex Therapeutics (ASX:IXC) proposed buying Rekover Therapeutics and raising A$10 million for a multiple sclerosis trial. The deal would more than triple its share count, so shareholder approval matters. Cynata Therapeutics (ASX:CYP) raised about A$913,000 after shareholders took up only 25.8% of the offer. The underwriter must provide most of the money.
Immutep (ASX:IMM) is narrowing its cancer programme after its large lung cancer trial failed to show enough benefit. The company found structural differences between manufacturing batches and plans a new 200-litre production run. It had A$68.9 million in cash and term deposits, which management expects to last into the first half of 2028 under current plans. That gives time to test the remaining programmes, but the failed trial has made the next evidence more important.
This Week's Sector Wraps
Compare performance across the market
Bottom Line?
The next major tests are close. Actinogen expects XanaMIA Alzheimer’s results in mid-November 2026. Noxopharm is due to announce a capital raising by 2 November 2026 unless it reports sooner. Radiopharm expects to begin its RAD101 Phase 3 trial in the first quarter of 2027, while Clarity expects key imaging results in the first half of 2027. Investors will judge these events against each company’s cash balance and need for new funding.
Questions in the middle?
- Can AdAlta secure enough funding to move EW-001 through its FDA meeting and Australian manufacturing work?
- Will Mesoblast’s higher Ryoncil sales continue while it prepares possible FDA filings?
- Can companies with less than one quarter of cash, including Chimeric and Nexalis, complete new funding before clinical work stops?
Sources
23This wrap draws on announcements from 23 companies. For the full story and each verified source, see the company's own article:
ASX:1AD, ASX:ALA, ASX:AT1, ASX:BDX, ASX:BIO, ASX:BOT, ASX:CAN, ASX:CHM, ASX:CU6, ASX:CYC, ASX:CYP, ASX:IDX, ASX:IMM, ASX:IXC, ASX:LDX, ASX:MSB, ASX:NTI, ASX:NX1, ASX:RAD, ASX:SKN, ASX:TRP, ASX:VBS, NZX:TAH
